By Finance Pulse in stock plunge —

Neumora Therapeutics Shares Plummet 80% After Drug Trial Failure

Neumora Therapeutics stock plummets 80% to $2.05 after pivotal Phase 3 trial of their depression drug fails, impacting investor confidence.

A graph illustrating a sharp decline in stock prices, with a backdrop of muted colors to convey the
Neumora Therapeutics Shares Plummet 80% After Drug Trial Failure

Neumora Therapeutics shares plunged 80% to $2.05 after their depression drug failed in Phase 3 trials.

Source